UB Paderborn / Katalog / Suche / in CDI

A1 adenosine receptor agonists and their potential therapeutic applications

Expert opinion on investigational drugs, 2008-12, Vol.17 (12), p.1901-1910

2008

Link zum Volltext

Verfügbarkeit prüfen

Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists

The Journal of pharmacology and experimental therapeutics, 2001-07, Vol.298 (1), p.209

2001

Link zum Volltext

Verfügbarkeit prüfen

960 TT-816, a novel small molecule immune checkpoint inhibitor targeting cannabinoid CB2 receptor, stimulates innate and adaptive immunity for cancer therapy

Journal for immunotherapy of cancer, 2022-11, Vol.10 (Suppl 2), p.A1001-A1001

2022

Link zum Volltext

Verfügbarkeit prüfen

Abstract 55: TT-702, a selective and potent A2B receptor antagonist for the treatment of cancer

Cancer research (Chicago, Ill.), 2021-07, Vol.81 (13_Supplement), p.55-55

2021

Link zum Volltext

Verfügbarkeit prüfen

A1 adenosine receptor antagonists, agonists, and allosteric enhancers

Handbook of experimental pharmacology, 2009 (193), p.25

2009

Link zum Volltext

Verfügbarkeit prüfen

The novel late Na+ current inhibitor, GS‐6615 (eleclazine) and its anti‐arrhythmic effects in rabbit isolated heart preparations

British journal of pharmacology, 2016-11, Vol.173 (21), p.3088-3098

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I Nai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties

Journal of medicinal chemistry, 2016-10, Vol.59 (19), p.9005-9017

2016

Link zum Volltext

Verfügbarkeit prüfen

A 1 adenosine receptor agonists and their potential therapeutic applications

Expert opinion on investigational drugs, 2008-12, Vol.17 (12), p.1901-1910

2008

Link zum Volltext

Verfügbarkeit prüfen

The novel late Na super(+) current inhibitor, GS-6615 (eleclazine) and its anti-arrhythmic effects in rabbit isolated heart preparations

British journal of pharmacology, 2016-11, Vol.173 (21), p.3088-3098

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a Novel A2B Adenosine Receptor Antagonist as a Clinical Candidate for Chronic Inflammatory Airway Diseases

Journal of medicinal chemistry, 2008-04, Vol.51 (7), p.2267-2278

2008

Link zum Volltext

Verfügbarkeit prüfen

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine

Bioorganic & medicinal chemistry letters, 2016-07, Vol.26 (13), p.3202-3206

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)

Bioorganic & medicinal chemistry letters, 2018-02, Vol.28 (3), p.541-546

2018

Link zum Volltext

Verfügbarkeit prüfen

Selective, high affinity A(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Bioorganic & medicinal chemistry letters, 2008-02, Vol.18 (4), p.1397-1401

2008

Link zum Volltext

Verfügbarkeit prüfen

Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late I Na i) of the cardiac Na v 1.5 channel with improved efficacy and potency relative to ranolazine

Bioorganic & medicinal chemistry letters, 2016-07, Vol.26 (13), p.3207-3211

2016

Link zum Volltext

Verfügbarkeit prüfen

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late I Na i) of the cardiac Na V 1.5 channel with improved efficacy and potency relative to ranolazine

Bioorganic & medicinal chemistry letters, 2016-07, Vol.26 (13), p.3202-3206

2016

Link zum Volltext

Verfügbarkeit prüfen

A2B adenosine receptor antagonists and their potential indications

Expert opinion on therapeutic patents, 2006-10, Vol.16 (10), p.1347-1357

2006

Link zum Volltext

Verfügbarkeit prüfen

Selective, high affinity A2B adenosine receptor antagonists : N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Bioorganic & medicinal chemistry letters, 2008-02, Vol.18 (4), p.1397-1401

2008

Link zum Volltext

Verfügbarkeit prüfen

Novel 1,3-Disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) Xanthines: High Affinity and Selective A2B Adenosine Receptor Antagonists

Journal of medicinal chemistry, 2006-06, Vol.49 (12), p.3682-3692

2006

Link zum Volltext

Verfügbarkeit prüfen

Synthesis, Antifolate, and Antitumor Activities of Classical and Nonclassical 2-Amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines

Journal of medicinal chemistry, 2001-06, Vol.44 (12), p.1993-2003

2001

Link zum Volltext

Verfügbarkeit prüfen

Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists

Bioorganic & medicinal chemistry letters, 2006-01, Vol.16 (2), p.302-306

2006

Link zum Volltext

Verfügbarkeit prüfen

A 2B adenosine receptor antagonists and their potential indications

Expert opinion on therapeutic patents, 2006-10, Vol.16 (10), p.1347-1357

2006

Link zum Volltext

Verfügbarkeit prüfen

Discovery of a Novel A 2B Adenosine Receptor Antagonist as a Clinical Candidate for Chronic Inflammatory Airway Diseases

Journal of medicinal chemistry, 2008-04, Vol.51 (7), p.2267-2278

2008

Link zum Volltext

Verfügbarkeit prüfen

Using Patchxpress to Screen Blockers of the Cardiac Sodium Channel (Nav1.5) for Effects on Late INA, Peak INA, and Channel Kinetics

Biophysical journal, 2010-01, Vol.98 (3), p.113a-113a

2010

Link zum Volltext

Verfügbarkeit prüfen

Selective, high affinity A sub(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Bioorganic & medicinal chemistry, 2008-02, Vol.18 (4), p.1397-1401

2008

Link zum Volltext

Verfügbarkeit prüfen

Selective, high affinity A 2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Bioorganic & medicinal chemistry letters, 2008, Vol.18 (4), p.1397-1401

2008

Link zum Volltext

Verfügbarkeit prüfen

Menü

Weitere Dienste

Einstellungen

A1 adenosine receptor agonists and their potential therapeutic applications

Novel short-acting A2A adenosine receptor agonists for coronary vasodilation: inverse relationship between affinity and duration of action of A2A agonists

960 TT-816, a novel small molecule immune checkpoint inhibitor targeting cannabinoid CB2 receptor, stimulates innate and adaptive immunity for cancer therapy

Abstract 55: TT-702, a selective and potent A2B receptor antagonist for the treatment of cancer

A1 adenosine receptor antagonists, agonists, and allosteric enhancers

The novel late Na+ current inhibitor, GS‐6615 (eleclazine) and its anti‐arrhythmic effects in rabbit isolated heart preparations

Discovery of Dihydrobenzoxazepinone (GS-6615) Late Sodium Current Inhibitor (Late I Nai), a Phase II Agent with Demonstrated Preclinical Anti-Ischemic and Antiarrhythmic Properties

A 1 adenosine receptor agonists and their potential therapeutic applications

The novel late Na super(+) current inhibitor, GS-6615 (eleclazine) and its anti-arrhythmic effects in rabbit isolated heart preparations

Discovery of a Novel A2B Adenosine Receptor Antagonist as a Clinical Candidate for Chronic Inflammatory Airway Diseases

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late INai) of the cardiac NaV 1.5 channel with improved efficacy and potency relative to ranolazine

Discovery of potent and selective inhibitors of calmodulin-dependent kinase II (CaMKII)

Selective, high affinity A(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Discovery of triazolopyridinone GS-462808, a late sodium current inhibitor (Late I Na i) of the cardiac Na v 1.5 channel with improved efficacy and potency relative to ranolazine

Discovery of triazolopyridine GS-458967, a late sodium current inhibitor (Late I Na i) of the cardiac Na V 1.5 channel with improved efficacy and potency relative to ranolazine

A2B adenosine receptor antagonists and their potential indications

Selective, high affinity A2B adenosine receptor antagonists : N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Novel 1,3-Disubstituted 8-(1-benzyl-1H-pyrazol-4-yl) Xanthines: High Affinity and Selective A2B Adenosine Receptor Antagonists

Synthesis, Antifolate, and Antitumor Activities of Classical and Nonclassical 2-Amino-4-oxo-5-substituted-pyrrolo[2,3-d]pyrimidines

Novel 1,3-dipropyl-8-(1-heteroarylmethyl-1H-pyrazol-4-yl)-xanthine derivatives as high affinity and selective A2B adenosine receptor antagonists

A 2B adenosine receptor antagonists and their potential indications

Discovery of a Novel A 2B Adenosine Receptor Antagonist as a Clinical Candidate for Chronic Inflammatory Airway Diseases

Using Patchxpress to Screen Blockers of the Cardiac Sodium Channel (Nav1.5) for Effects on Late INA, Peak INA, and Channel Kinetics

Selective, high affinity A sub(2B) adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Selective, high affinity A 2B adenosine receptor antagonists: N-1 monosubstituted 8-(pyrazol-4-yl)xanthines

Suchergebnisse filtern